Polymerase chain reaction (PCR) assessment of clonal immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements is an important diagnostic tool in mature B-cell neoplasms. However, lack of standardized PCR protocols resulting in a high level of false negativity has hampered comparability of data in previous clonality studies. In order to address these problems, 22 European laboratories investigated the Ig/TCR rearrangement patterns as well as t(14;18) and t(11;14) translocations of 369 B-cell malignancies belonging to five WHO-defined entities using the standardized BIOMED-2 multiplex PCR tubes accompanied by international pathology panel review. B-cell clonality was detected by combined use of the IGH and IGK multiplex PCR assays in all 260 definitive cases of B-cell chronic lymphocytic leukemia (n ¼ 56), mantle cell lymphoma (n ¼ 54), marginal zone lymphoma (n ¼ 41) and follicular lymphoma (n ¼ 109). Two of 109 cases of diffuse large B-cell lymphoma showed no detectable clonal marker. The use of these techniques to assign cell lineage should be treated with caution as additional clonal TCR gene rearrangements were frequently detected in all disease categories. Our study indicates that the BIOMED-2 multiplex PCR assays provide a powerful strategy for clonality assessment in B-cell malignancies resulting in high Ig clonality detection rates particularly when IGH and IGK strategies are combined.
Introduction
Despite well established morphological and immunophenotypic criteria a definitive diagnosis cannot be provided in all cases of mature B-cell neoplasms. The use of molecular clonality testing in cases with suspected lymphoproliferations is thought to produce valuable additional information. Although still considered the 'gold standard', laborious and expensive Southern hybridization procedures have largely been replaced by PCRbased technology. This PCR approach has relied primarily on the amplification of rearranged immunoglobulin heavy chain (IGH) genes to diagnose clonality in B cell disorders, using conserved sequences within the framework regions of the IGH gene to design primers. Earlier studies have used a strategy based upon the design of consensus primers within the V H and J H regions [1] [2] [3] or family-specific V H primers in combination with a consensus J H primer. [4] [5] [6] [7] Although these studies were highly sensitive and generally informative, both approaches are suboptimal and suffer from false negativity in a proportion of cases when compared with Southern hybridization results.
A number of factors impaired the initial PCR-based approaches, such as ineffective primer binding owing to imprecise annealing of the primers to all potential V and J segments. A second factor is the occurrence of somatic hypermutation (SHM) in the Ig genes of germinal center (GC) and post-germinal center (post-GC) lymphomas. The acquisition of somatic mutations can therefore be used to assign the stage of B-cell development of a given leukemia or lymphoma based upon the presence or absence of SHM. 8 The mechanism of SHM is well described. Coupled to transcription, SHM occurs within a small defined (1.5-2 Kb) region of DNA and is initiated from the transcriptional promoter 300 bp upstream of each rearranged V segment; the process is terminated immediately downstream of the involved J segment. [9] [10] [11] These point mutations occur over the entire length of the V-D-J exon of the IGH genes and the V-J exon of the IGK and IGL genes. Mutations within the binding site of either the V or J primer can lead to ineffective binding and lack of PCR amplification. Logically, V H -J H primer sets can also not detect incomplete D H -J H rearrangements, which are frequently found in a spectrum of B-cell disease subtypes. 12, 13 D H -J H rearrangements have been shown to occur in up to 60% of multiple myeloma cases. 14 This type of joining provides an excellent target for PCR-based clonality studies, as the majority of these rearrangements do not show SHM. 15 Amplification of alternative clonal targets has been used to overcome these problems. The use of immunoglobulin light chain gene (IGK and IGL) rearrangements has been applied to clonality testing. [16] [17] [18] Containing no diversity region (D) segments, functional IGK recombinations involve V k -J k joinings. Inactivating rearrangements occur involving the kappa-deleting element (Kde) and a V k gene segment or an intronic recombination sequence signal (intronRSS) lying between the J k and C k segments. Both these types of Kde recombinations result in the inactivation of the IGK allele. Both functional (V k -J k ) and inactive IGK rearrangements (V k -Kde and intronRSS-Kde) are detectable using PCR-based strategies. 16, 17, 19 The IGL gene on chromosome 22q11.2 may also be a suitable target for clonality studies as 5-10% of Igk expressing malignancies and all Igl-positive cases show rearrangements at this locus. [19] [20] [21] Chromosomal translocations involving the IGH locus are frequently observed in B-cell malignancies. The t(14;18) (q32;q21) and t(11;14)(q13;q32) are the molecular hallmarks of follicular lymphoma (FL) and mantle cell lymphoma (MCL), respectively. Both translocations are well characterized at the molecular level and owing to the clustering of breakpoints within the BCL2 and BCL1 loci are amenable to PCR detection and can serve as alternative markers of clonality. [22] [23] [24] [25] To try to address many of these problems, we recently developed standardized PCR protocols with multiplex PCR tubes (BIOMED-2 Concerted Action BMH4-CT98-3936). 19 Thirty experienced PCR laboratories took part in a validation exercise on 90 Southern blot and histologically defined lymphoproliferative and reactive cases using standardized protocols for most B-cell and T-cell receptor targets. However, the numbers for individual disease categories were too small to evaluate the contribution of this comprehensive PCR strategy. In order to corroborate these data, we have collected a larger series of 369 mature B-cell malignancies as defined by the WHO classification 26 and used the BIOMED-2 multiplex PCR tubes to evaluate their clonal status. These disease categories were selected to represent malignancies at different stages of B-cell differentiation, that is typical examples of pre-germinal center (pre-GC), GC and post-GC lymphoma with differing levels of SHM and the potential presence of translocations involving the IGH gene.
Materials and methods

Sample collection and histological review
Seven national networks collected 402 newly diagnosed or frozen samples, all analysis was performed on anonymised, surplus diagnostic material according to the local ethical agreements in individual centres. Tissue was collected from five different B-cell disease categories, MCL, B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/ SLL), FL, marginal zone lymphoma (MZL) and diffuse large B-cell lymphoma (DLBCL). Diagnosis was initially based upon the clinical, histological and immunophenotypic procedures carried out locally at the referring institution. Samples were only selected if sufficient good quality material was available to extract 100 mg of DNA. All samples were assessed for quality and amplifiability using the BIOMED-2 control gene primer set 19 and only samples with DNA amplifiable above 400 bp were included in the study. In each country, a national pathology review panel re-examined all cases. A further 10% of all cases plus problematic ones (non-concordance between morphology and immunophenotype or difficult interpretation of the results) were also reviewed by the BIOMED-2 pathology review panel (Supplementary Figure 1) . The final diagnosis was established after a consensus was obtained. This phase of the review resulted in 22 cases being removed from the study, owing to either a misdiagnosis or a clerical error in the referring laboratory. In addition, 14/380 cases were reassigned to a different B-cell disease category.
A third phase of review, performed after completion of the molecular study, included all cases with unusual results and in particular those without a detectable clonal rearrangement or translocation. In these latter cases, if available, a frozen section of the block from which DNA was extracted was obtained to confirm the presence of the lesion and to ascertain the tumour load. Nine of the DLBCL cases underwent this review. Two of these cases had a diagnosis of DLBCL confirmed by panel review and were restored to the study. In the remaining seven cases, a definitive diagnosis of DLBCL could not be established. In three cases, pathology review confirmed a diagnosis of NLPHD (nodular lymphocyte predominant Hodgkin lymphoma). In three further DLBCL cases and in a single case of MZL, panel review was not undertaken, as diagnostic material was unavailable. In the remaining DLBCL case and in three MZL cases, histology of the frozen section used to prepare DNA showed minimal or no evidence of lymphoma with insufficient data to differentiate them from lymphoid hyperplasia. All eleven cases were removed from the study. Consequently, the remaining series of 369 B-cell malignancies consisted of 54 MCL cases, 56 B-CLL/SLL cases, 109 FL cases, 41 MZL cases and 109 DLBCL cases.
PCR studies
This study was performed within the framework of the BIOMED-2 Concerted Action BMH-CT98-3936. Twenty-two of the 30 BIOMED-2 molecular diagnostic laboratories from seven European countries (Belgium, France, Germany, The Netherlands, Portugal, Spain and UK) participated in the molecular testing of the mature B-cell malignancies with four participating laboratories for each of the MCL, CLL/SLL and MZL categories. The FCL and DLBCL categories contained far larger numbers of cases and were analysed in eight different laboratories. Five disease category leaders carried out data collection and co-ordination of the different groups (Supplementary Figure 1) . All samples were analysed in duplicate using the BIOMED-2 protocols and multiplex primer sets: IGH (V H -J H and D H -J H ), IGK (V k -J k and Kde primers), IGL, TCRB (V b -J b and D b -J b ), TCRG, TCRD, t(14;18) and t (11;14) . 19 In order to help ensure consistency between laboratories, a large-scale synthesis of the 107 different primers was produced by Sigma-Genosys Ltd (Pampisford, UK), aliquoted in Rotterdam and distributed to all participants. The BIOMED-2 multiplex PCR tubes are currently available from InVivoScribe Technologies (San Diego, CA, USA) (www.invivoscribe.com).
Each sample was tested in two separate laboratories by both GeneScanning and heteroduplex analysis. In three laboratories, GeneScan analysis was not available; in these laboratories, heteroduplex analysis was performed in duplicate on all cases. This resulted in each individual case being analysed at least four times. Concordant results were seen between laboratories in the majority of cases (495%). In a minority, discrepancies occurred either between the two laboratories for a particular target or between the two detection techniques. In these situations, a third laboratory, assigned by the disease category leader, performed re-analysis. Cases requiring re-analysis were not biased to any particular disease category; more frequently reanalysis was performed due to a disagreement between heteroduplex and GeneScan results, particularly within the IGK tubes. This can be explained by the restricted CDRIII region in these rearrangements, leading to difficult clonality interpretation, particularly using GeneScan technology. 19 Results Table 1 summarizes the clonality profiles for the five disease categories. Using the BIOMED-2 multiplex strategy, 367/369 cases (99%) demonstrated at least one clonal Ig rearrangement. 
Mantle cell lymphoma
All 54 cases of MCL demonstrated clonal IGH V H -J H rearrangements in at least two tubes, with amplification in the FR1 and FR2 tubes being most prevalent (Table 3) . Incomplete D H -J H rearrangements were rare in this category with an incidence of only 6/54. Clonal Ig light chain rearrangements could also be detected with a high frequency in this disease category; a clonal IGK rearrangement was found in all cases investigated with 51/54 (94%) showing a V k -J k rearrangement and 40/54 (75%) showing a rearrangement involving the Kde V k -Kde or intronRSS-Kde. As Kde rearrangements frequently occur in Igl þ B-cell non-Hodgkin's lymphoma, it was predictable that all 24 Igl þ cases showed a Kde rearrangement and 20 samples had both types of IGK rearrangements (V k -J k and Kde) detectable. The assessment of IGL clonality did not provide additional information for Ig light chain clonality status.
In 19 (35%) of the cases, the characteristic chromosomal translocation t (11;14) was detected by PCR analysis of the major translocation cluster (MTC) region. All cases lacking a PCR detectable t(11;14) translocation were then selected for an international pathology panel review process and the diagnosis of MCL was confirmed, based on cyclin D1 expression. Table 1 Genotypic profiles in five categories of mature B-cell malignancy TCRD genes 2 (4) 7 (12) 5 (5) 3 (10) 2 (20) 15 (14) 35 (9) Total TCR (%) 9 (16) 21 (38) 14 (13) 11 (35) 5 (50) 36 (33) 98 (27) Abbreviations: CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; intronRSS, intronic recombination sequence signal; Kde, kappa-deleting element; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; SLL, small lymphocytic lymphoma; TCR, T-cell receptor.
a Combinations of two Ig gene rearrangements that are virtually unaffected by somatic mutations.
Significantly improved PCR-based clonality testing in B-cell malignancies PAS Evans et al
TCR clonality was demonstrated in 9/54 (16%) of all MCL. In four cases, the TCRG and TCRB clonality may have resulted from admixed rare T-cells with a restricted repertoire or from a clonal expansion of T-cells. Five cases showed TCR rearrangements with only one primer set: three cases showing TCRG clonality and two cases showed isolated TCRD and D b -J b positivity, respectively; these latter cases probably represent true cross-lineage TCR gene rearrangements.
Chronic lymphocytic leukemia
All 56 cases of CLL showed a detectable clonal V H -J H rearrangement. In a single case, a weak clonal FR1 PCR product was detected as the sole V H -J H rearrangement. This case however had a clear clonal IGK rearrangement. None of the cases showed a t(11;14) by PCR, but a single case showed a t(14;18) this case was reviewed by the panel and was confirmed to be CLL/SLL. In contrast to MCL, clonal incomplete D H -J H rearrangements were observed in 24/56 cases (43%).
All cases also possessed at least one clonal Ig light chain gene rearrangement. IGK rearrangements were detectable in all cases studied, with 54/56 (96%) of cases showing a V k -J k rearrangement and 34/56 (61%) of cases either a V k -Kde or intronRSS-Kde rearrangement. In addition 17/56 (30%) of cases also had a clonal IGL gene rearrangement. In 2/17 cases, these had occurred in the absence of any detectable Kde rearrangement. In two of the 10 cases that demonstrated expression of a Igl light chain, no IGL gene rearrangement could be detected, indicating that the BIOMED-2 V l -J l primers do not detect all IGL rearrangements. Conversely, of the 23 cases that expressed Igk light chains, two of the cases showed a rearranged IGL gene.
Clonal TCR gene rearrangements were detected in 21/56 (38%) of cases with 14/56 (25%) showing a TCRB rearrangement, 10/56 (18%) a TCRG rearrangement and 7/56 (12%) a TCRD rearrangement. In most instances, they appeared as weak dominant PCR products corresponding probably to minor clonal T-cell populations. Interestingly, in three cases, strong clonal incomplete D b -J b rearrangements were observed in the absence of any other TCR gene rearrangement; these TCRB gene rearrangements most probably represent true cross-lineage rearrangements. Table 2 The majority of mature B-cell malignancies can be identified by the use of three IGH (V H -J H ) tubes and two IGK (V k -J k and Kde) tubes From a diagnostic perspective, the incidence of TCR gene rearrangements in this common B-cell disorder is an important figure to know: 13% of cases had an identifiable TCR rearrangement, comprising D b -J b 4/109 (4%), V b -J b 3/109 (3%), TCRG 2/109 (2%) and TCRD 5/109 (5%). In all these cases, the clonal TCR gene rearrangement was only detected at one locus. This pattern of recombination would indicate that these most probably represent true cross-lineage rearrangements present within the malignant B-cell population.
Marginal zone lymphoma
A definitive diagnosis of MZL was confirmed in 41 cases, 31 were classified as extra-nodal MZL of MALT type and 10 cases were nodal MZL ( Table 1) . None of the 41 cases showed either a t(11;14) or t(14;18).
All 41 cases examined had a detectable clonal Ig gene rearrangement. A clonal IGH V H -J H gene rearrangement was identified in 36/41. In three cases, the presence of a clonal B-cell population was exclusively shown by a D H -J H amplification in the absence of detectable V H -J H rearrangements and in one case, this was the sole clonality marker detected. Rearranged IGK genes, both the V k -J k and Kde rearrangements, were identified in 34/41 cases. Combining IGH and IGK rearrangements, we were able to detect a clonal population in all MZL cases. Performing the multiplex PCR for detection of IGL gene rearrangements did not add to the number of clonal samples.
Clonal TCR rearrangements were frequently identified in MZL, occurring in both extranodal 11/31 (35%) and nodal cases 5/10 (50%). In the majority of these cases 9/41 (22%), an incomplete D b -J b gene rearrangement was detected, either on its own or in combination with a V b -J b (3/9) or V g -J g (3/9). TCRD rearrangements were also identified in 5/41 (12%) cases, 4/41 in isolation and in a single case in combination with V b -J b .
Diffuse large B-cell lymphoma
One hundred and nine cases were finally evaluated in the DLBCL category after extensive pathological review. Using IGH rearrangements as a marker, we were able to detect complete V H -J H rearrangements in 79% of cases. The incidence of incomplete D H -J H rearrangements was 30% with seven of 109 (6%) cases having an isolated D H -J H rearrangement in the absence of a V H -J H joining. Utilizing a combination of V k -J k and Kde primers, 80% of DLBCL cases had a detectable IGK rearrangement. IGL rearrangements were detected in 28% of cases, two cases showed an IGL rearrangement in the absence of an IGK rearrangement.
The t(14;18) is consistently detected in a sub-group of DLBCL. Using the t(14;18) primer combinations, it was possible to detect an MBR rearrangement in 6/109 (6%), 3 0 MBR in 2/109 (2%) and MCR/5 0 MCR in 5/109 (5%). Using this comprehensive PCR strategy, the t(14;18) was detectable in 13% of cases.
In 2/109 cases, no detectable clonal marker and/or translocation could be identified.
T-cell clonality was detected in 36/109 (33%) of the DLBCL cases. TCRB rearrangements were detected in 23/109 (21%) samples: 17/23 were incomplete D b -J b junctions and 14/23 were complete V b -J b rearrangements. TCRG rearrangements were detectable in 16/109 (15%) cases and TCRD 15/109 (14%). In the majority of these cases, the TCR rearrangement was detectable in isolation, however, in 11/109 (10%) of cases rearrangements were demonstrated at more than one locus, 9/11 cases showed coexisting TCRB and TCRG and 2/11 TCRG and TCRD rearrangements.
Discussion
The fundamental aim of this study was to improve the reliability of clonality testing in WHO classification defined mature B-cell malignancies. Langerak et al. 27 in an accompanying article in this issue have applied the BIOMED-2 multiplex PCR tubes to a large series of tissues from a variety of reactive lesions and shown that this strategy can be used to provide a definitive diagnosis in all cases.
Traditionally, IGH V H -J H rearrangements are used to detect B-cell clonality. [1] [2] [3] [4] [5] [6] [7] In this study, combining data from the V H -J H FR1, -2 and -3 multiplex tubes provided additional information in all disease categories (Table 3 ). All malignancies showing a naïve, pre-GC immunophenotype had a detectable VDJ rearrangement, with all three IGH multiplex tubes giving comparable results. It is perhaps surprising that the detection rate in the CLL/SLL category was excellent using all three multiplex tubes, because it is now well documented that approximately half of all CLL patients harbour SHM. 28 However, the effects of SHM can clearly be seen when directly comparing IGH V H -J H amplification in the pre-GC categories, with the level of detection using V H -J H FR1, -2 and -3 multiplex tubes consistently higher in MCL compared with CLL/SLL (Table 3) . Disease categories traditionally associated with high levels of SHM (FL, MZL and DLBCL) had a lower level of detection using the three V H -J H multiplex tubes; in general, the FR1 and FR2 multiplex tubes were superior for clonality detection compared with the FR3 (Table 3) . A possible explanation for the superior detection rates seen with the FR1 and FR2 multiplex could be that SHM is targeting mutational hotspots close to the CDRIII region (reviewed by Jolly 29 ). Alternatively, excessive exonuclease activity at the V H -D H and D H -J H junctions can also result in loss of primer binding, although the J H primer was designed to bind 410-15 bp from the junctional region, and much further than this in the case of the V H FR3 primers. In a large series of multiple myeloma cases, the improved detection rate with the BIOMED-2 multiplex strategy has recently also been corroborated. In this series, Gonzalez et al.
14 were able to detect V H -J H rearrangements in the presence of marked SHM (range 2.2-20.8%, median 7.2%) in the majority of cases (84%).
Theoretically, SHM should not occur in D H -J H rearrangements as they lack the transcriptional promoter necessary to initiate the process. 9, 10, 14 The investigation of incomplete rearrangements in our study did show some interesting results: high frequencies of incomplete D H -J H rearrangements were seen in CLL/SLL, MZL and DLBCL and less frequently in the MCL and FL categories. In all positive cases of MCL and CLL/ SLL, an IGH V H -J H rearrangement was identified as well. However, in the three disease categories associated with high levels of SHM, D H -J H rearrangements were identified in the absence of any V H -J H joining in a small number of cases. These data would therefore confirm that incomplete rearrangements do provide supplementary information, particularly in the presence of SHM. 14, 15 Although the three-tube IGH V H -J H multiplex strategy was designed to try and overcome the effects of SHM occurring within the V H region, it is more difficult to overcome mismatches when they occur within the J H segment. The consensus primer used in this study has mismatches to five of the six J H segments. 30 Although these mismatches were predominantly at the 5 0 end of the primer, additional mismatches resulting from SHM may be sufficient to destabilize primer binding. The use of multiple J H primers with complete homology to all potential J H segments has been shown to improve the performance of conventional V H -J H PCR. 7 Detection of Ig light chain gene rearrangements, particularly IGK, has proven to be an excellent alternative target to IGH V H -J H rearrangements for B-cell clonality assessment. Theoretically, all mature B-cell malignancies should possess IGK rearrangements, regardless of light chain expression. IGK rearrangements were indeed detectable in all cases of CLL/SLL and MZL. In general, all disease categories showed a higher percentage of functional V k -J k rearrangements compared to V k -Kde or intronRSS-Kde rearrangements. In the GC and post-GC lymphoma cases, the detection rate using the IGK multiplex assays was comparable to the detection rates seen using the IGH V H -J H strategy. Detection of IGL rearrangements did not contribute additional information, this was particularly so in the pre-GC lymphoma categories.
Integrating the data from IGH and Ig light chain rearrangements, particularly V H -J H and IGK, provide the most remarkable information in this study. In both CLL/SLL and MCL, every case studied had a coexisting IGH and IGK rearrangement. Complementarity of this approach appears to be particularly important in cases of GC and post-GC lymphoma. This is exemplified by the combined use of IGH V H -J H and IGK in FL, which confirmed the clonal origin in all 109 cases. This level of detection in FL is far higher than previous studies, which employed either a single target for clonality detection, 31 or even in studies exploiting several different PCR strategies to detect IGH V H -J H rearrangements. 32 Two panel reviewed DLBCL cases failed to exhibit any evidence of clonality. A single case had histological features of T-cell rich DLBCL. In this case, the number of clonal B cells might be too low for successful demonstration of clonality. The second negative case was reviewed in both the diagnostic paraffin embedded and frozen tissue used to prepare DNA. This most likely represents an exceptional case with a significant degree of SHM in the absence of either an incomplete D H -J H rearrangement or identifiable t (14;18) . A further possibility is that this represents a clerical/sample-labelling error following diagnosis but before DNA distribution.
Using clonality studies to assign lineage is potentially an attractive proposition. This study has demonstrated that in a substantial number of mature B-cell malignancies (27%), coexisting clonal TCR rearrangements can be detected. The incidence of cross-lineage TCR gene rearrangements is well documented in precursor B-acute lymphoblastic leukemia, occurring in up to 90% of cases. 33 These cross-lineage rearrangements provide very useful alternative targets with which to monitor residual disease in this setting. 34, 35 Likewise, crosslineage Ig rearrangements are also frequently detectable in a minority of T-cell malignancies. 36 The incidence of clonal TCR gene rearrangements in mature B-cell malignancies is less well established but has been reported. 37 In this study, clonal TCR rearrangements were most frequently observed in MZL, CLL and DLBCL. Two patterns of TCR gene rearrangements were detectable. Isolated rearrangements usually showing a strong clonal pattern and involving a single locus accounted for 11% (41/369) of cases and were most frequent in the DLBCL category (25/109). These rearrangements frequently involved incomplete D b -J b joins. A further TCR pattern was seen in 16% (57/369) of cases, this pattern was particularly frequent in the CLL category (17/56), but also present in other B-cell categories. In these, TCR rearrangements could be identified at two or more loci, usually showing a weak clonal pattern, and is likely that coexisting clonal T-cell populations were present. A further explanation would be pseudoclonality because of low numbers of clonally related T-cells. Analysing a large series of well-defined reactive lesions, Langerak et al. 27 found a similar spectrum of TCR gene rearrangements. Chromosomal translocations involving the Ig genes are frequently detectable in mature B-cell neoplasms. Comprehensive strategies to identify the t(11;14) and t(14;18) were also developed by the BIOMED-2 group. These strategies were applied to all cases in this study. Amplification of the t(11;14) using primers to the MTC region were detected only in 19/54 (35%) MCL cases and negative in all other categories, which is broadly comparable to other published series. 24, 25 Clonality assessment using the BIOMED-2 t(11;14) strategy did not however contribute because all MCL cases also had a detectable V H -J H rearrangement. On the other hand, PCR detection of the translocation in approximately 40% of MCL with a t (11;14) , is suitable for the classification of MCL.
Identification of the t(14;18) using the three BCL2 multiplex tubes was applied to all disease categories and was found to be restricted to cases of FL and DLBCL and a single confirmed case of CLL/SLL. The overall incidence of the t(14;18) in the DLBCL category was 13%, lower than reported in previous studies. 38, 39 The incidence of the translocation in FL was 60%; the multiplex strategy described is capable of detecting 88% of cytogenetically positive cases. 19 Pathological review of the t(14;18)-negative cases showed a higher incidence of grade III disease as compared with the whole series, which has been shown to have a lower incidence of the t(14;18). 40 Interestingly, the t(14;18)-positive cases collected within the different national networks appeared to show a geographical bias with regard to detecting the translocation. Cases submitted from the Iberian peninsula (Spain and Portugal) showed a particularly low level of t(14;18) positivity (21%); this is related to a higher percentage of grade III cases from Spain. However, this information was gathered from the initial reports and could not be verified by us.
The DNA used to perform this study was extracted from fresh and/or frozen samples. The use of the BIOMED-2 multiplex PCR strategies on DNA derived from paraffin embedded, formalin fixed tissue was not investigated in this study but has previously been shown to be applicable to this type of tissue provided that amplifiable DNA above 300 bp is used as assessed by the use of the Biomed-2 Control Gene tube. 19 
Conclusion
We have investigated the clonality profiles of 369 WHO classification defined mature B-cell malignancies and shown that the BIOMED-2 multiplex tubes perform extremely well in all disease categories irrespective of their SHM status. In a routine diagnostic setting, it is not practical to perform the complete spectrum of PCR tubes on every case referred to the laboratory. By judicious combinations of these primer sets, it is possible to generate a clonal marker in almost all cases using a nominal number of multiplex tubes (Table 1) . Combining IGH and IGK strategies, in particular IGH V H -J H with IGK (V k -J k and Kde primers), employing only five multiplex tubes will demonstrate clonality in 98% of cases with confirmed histological evidence of disease (Table 2) . It is also beneficial to confirm the presence of clonality using two independent PCR targets whenever possible. In this study, we have demonstrated that this five-tube multiplex strategy is sufficiently robust to detect at least two clonal rearrangements in 89% (329/369) and three or more in 79% in all B-cell disease categories ( Table 2) .
Incomplete D H -J H rearrangements do provide a useful alternative marker, particularly in MZL and CLL and may be especially useful in cases lacking a V H -J H rearrangement. These rearrangements when present provide potentially excellent targets for MRD studies. 14 This and other studies recently carried out by the BIOMED-2 network have highlighted the potential problems of using clonality studies to both assign lineage and confirm a malignant process. 27, 33 Clonality studies should therefore always be used within the context of clinical, histological and immunophenotypic information.
